Conclusion: Our results indicates the importance of molecular screening the women with a history of 3 or more habitual abortions for these mutations.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Objective: To study the Factor II (prothrombin) G20210A and Factor V G1691A (FV-Leiden) mutations among women with habitual abortions.
📊
Key Findings & Data:Study Design: Thirty women who had 3 or more abortions were included in this study.
💡
Conclusion & Impact:Conclusion: Our results indicates the importance of molecular screening the women with a history of 3 or more habitual abortions for these mutations.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Düşük · kendiliğinden · Düşük
Abstract
Objective: To study the Factor II (prothrombin) G20210A and Factor V G1691A (FV-Leiden) mutations among women with habitual abortions. Study Design: Thirty women who had 3 or more abortions were included in this study. Molecular analysis of both prothrombin G20210A and factor V Leiden G1691A was performed using PCR and RFLP. Results: The ratios of FV heterozygote and homozygote patients were found as 16.7% and 3.3% respectively. Besides in 3.3% of patients Prothrombin G20210A GA heterozygote genotype was established and none of the patients showed FII homozygote genotype. Conclusion: Our results indicates the importance of molecular screening the women with a history of 3 or more habitual abortions for these mutations.
ERGÜN, M. A., SOYSAL, Y., AKAY, G. D., İMİRZALIOĞLU, N. (2005). Screening the women with habitual abortions for factor II G2021OA and factor V G1691A mutations in Turkish population. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 11 - Sayı: 2, 93–95. https://ajindex.com/articles/227116
Wramsby ML, Sten-Linder M, Bremme K. Primary habitual abortions are" associated with high frequency of factor V Leiden mutation. Fertil Steril 2000; 74:987-91.
Hohlagschwandtner M, Unfried G, Heinze G, Huber JC, Nagele F, Tempfer C. Combined thrombophilic poly morphisms in women with idiopathic recurrent miscarriage. Fertil Steril 2003; 79:1141-8.
Ridker PM, Miletich JP, Buring JE, Ariyo AA, Price DT, Manşon JE, Hill JA. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998; 128:1000-3.
Lucotte G, Champenois T. Duplex PCR-RFLP for simultaneous detection of factor V Leiden and prothrombin G20210A. Mol Cell Probes 2003; 17:267-9.
Murphy RP, Donoghue C, Nallen RJ, et al. Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase poly morphisms in pregnancy. Arterioscler Thromb Vase Biol 2000; 20:266-70.
Gandrille, M. Alhenc-Gelas and M. Aiach. A rapid screening method for the factor V arg 506-Gln mutation. Blood Coagul Fibrinolysis 1995; 6:245-8.
J. Danneberg, A.P. Abbes, BJ. Bruggeman et al. Reliable genotyping of the G-20210A mutation of coagulation factor II (prothrombin). Clin Chem 1998; 44:349-51.
Souza SS, Ferriani RA, Pontes AG, Zago MA, Franco RF. Factor V leiden and factor II G20210A mutations in patients with recurrent abortion. Hum Reprod. 1999; 14:2448-50.
Finan RR, Tamim H, Ameen G, Sharida HE, Rashid M, Almawi WY. Prevalence of factor V G1691A (factor V-Leiden) and prothrombin G20210A gene mutations in a recurrent miscarriage population. Am J Hematol 2002; 71:300-5.
Alonso A, Soto I, Urgelles MF, Corte JR, Rodriguez MJ, Pinto CR. Acquired and inherited thrombophilia in women with unexplained fetal losses. Am J Obstet Gynecol2002; 187:1337-42.
Foka ZJ, Lambropoulos AF, Saravelos H, Karas GB, Karavida A, Agorastos T, Zournatzi V, Makris PE, Bontis J, Kotsis A. Factor V leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod 2000; 15:458-62.
Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361:901-8.